Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe–Comparison of the Results of Multi-Center Registries

Maciej Kempa, Andrzej Przybylski, Szymon Budrejko, Tomasz Fabiszak, Michał Lewandowski, Krzysztof Kaczmarek, Mateusz Tajstra, Marcin Grabowski, Przemysław Mitkowski, Stanisław Tubek, Ewa Jędrzejczyk-Patej, Radosław Lenarczyk, Dariusz Jagielski, Janusz Romanek, Anna Rydlewska, Zbigniew Orski, Joanna Zakrzewska-Koperska, Artur Filipecki, Marcin Janowski, Tatjana Potpara and Serge Boveda
Additional contact information
Maciej Kempa: Department of Cardiology and Electrotherapy, Medical University of Gdansk, 80-210 Gdansk, Poland
Andrzej Przybylski: Medical College, University of Rzeszow, 35-959 Rzeszow, Poland
Szymon Budrejko: Department of Cardiology and Electrotherapy, Medical University of Gdansk, 80-210 Gdansk, Poland
Tomasz Fabiszak: Department of Cardiology and Internal Diseases, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland
Michał Lewandowski: 2nd Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
Krzysztof Kaczmarek: Department of Electrocardiology, Medical University of Lodz, 90-647 Lodz, Poland
Mateusz Tajstra: 3rd Department of Cardiology, Silesian Centre for Heart Diseases, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland
Marcin Grabowski: 1st Chair and Department of Cardiology, Medical University of Warsaw, 02-091 Warsaw, Poland
Przemysław Mitkowski: 1st Department of Cardiology, Chair of Cardiology, Karol Marcinkowski University of Medical Sciences, 61-701 Poznan, Poland
Stanisław Tubek: Department of Heart Diseases, Wroclaw Medical University, 50-367 Wroclaw, Poland
Ewa Jędrzejczyk-Patej: Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia Silesian Centre for Heart Diseases, 41-800 Zabrze, Poland
Radosław Lenarczyk: Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia Silesian Centre for Heart Diseases, 41-800 Zabrze, Poland
Dariusz Jagielski: Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, 50-981 Wroclaw, Poland
Janusz Romanek: Medical College, University of Rzeszow, 35-959 Rzeszow, Poland
Anna Rydlewska: Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, 31-008 Kraków, Poland
Zbigniew Orski: Department of Cardiology and Internal Diseases, Military Institute of Medicine, 04-141 Warsaw, Poland
Joanna Zakrzewska-Koperska: 1st Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
Artur Filipecki: 1st Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland
Marcin Janowski: Chair and Department of Cardiology, Medical University of Lublin, 20-059 Lublin, Poland
Tatjana Potpara: School of Medicine, Belgrade University, 11000 Belgrade, Serbia
Serge Boveda: Cardiology, Cardiac Arrhythmias Management Department, Clinique Pasteur, 31076 Toulouse, France

IJERPH, 2021, vol. 18, issue 13, 1-8

Abstract: The implantation of a subcutaneous cardioverter-defibrillator (S-ICD) may be used instead of a traditional transvenous system to prevent sudden cardiac death. Our aim was to compare the characteristics of S-ICD patients from the multi-center registry of S-ICD implantations in Poland with the published results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI). We compared data of 137 Polish S-ICD patients with 68 patients from the ESSS-SICDI registry. The groups did not differ significantly in terms of sex, prevalence of ischemic cardiomyopathy, concomitant diseases, and the rate of primary prevention indication. Polish patients had more advanced heart failure (New York Heart Association (NYHA) class III: 11.7% vs. 2.9%, NYHA II: 48.9% vs. 29.4%, NYHA I: 39.4% vs. 67.7%, p < 0.05 each). Young age (75.9% vs. 50%, p < 0.05) and no vascular access (7.3% vs. 0%, p < 0.05) were more often indications for S-ICD. The percentage of patients after transvenous system removal due to infections was significantly higher in the Polish group (11% vs. 1.5%, p < 0.05). In the European population, S-ICD was more frequently chosen because of patients’ active lifestyle and patients’ preference (both 10.3% vs. 0%, p < 0.05). Our analysis shows that in Poland, compared to other European countries, subcutaneous cardioverters-defibrillators are being implanted in patients at a more advanced stage of chronic heart failure. The most frequent reason for choosing a subcutaneous system instead of a transvenous ICD is the young age of a patient.

Keywords: sudden cardiac death; ventricular arrhythmia; implantable cardioverter-defibrillator; subcutaneous implantable cardioverter-defibrillator (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/13/7178/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/13/7178/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:13:p:7178-:d:588492

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().